目的 通过研究丙戊酸钠(sodium valproate,VPA)对体外培养的肺癌细胞株H1299细胞增殖、凋亡和细胞周期分布以及p21表达的影响,探讨其可能的作用机制。方法 用不同浓度(0、100、200、400、600、800 μmol·L-1 )丙戊酸钠处理人肺癌细胞株H1299不同时间(24、48、72 h)后, 四甲基偶氮唑蓝比色法检测细胞增殖,流式细胞技术分析细胞周期与细胞凋亡的改变,荧光定量聚合酶链反应分析p21 mRNA表达,Western blot分析p21蛋白表达。结果 丙戊酸钠能抑制肺癌细胞株H1299的增殖,使细胞阻滞于G1/G0期,诱导细胞凋亡。这些作用具有一定浓度和时间依赖性。丙戊酸钠能上调H1299细胞的p21表达。结论 丙戊酸钠通过阻滞细胞周期及诱导凋亡发挥体外抑制肺癌H1299细胞生长作用,其机制可能与上调p21表达有关。
Abstract
OBJECTIVE To preliminary investigate the effects of sodium valproate on the proliferation,the apoptosis and the cell cycle distribution and expression of p21 of lung cancer cell line H1299 in vitro,and to explore its possible mechanism. METHODS H1299 cells were treated with different concentrations (0, 100, 200, 400, 600, 800, 1 000 μmol·L-1) VPA with different length of time (24, 48,72 h);the cell proliferation was tested by MTT assay; the cell apoptosis and cell cycle distribution were analyzed by flow cytometry; test the expression of p21mRNA by Real-time PCR, and the expression of p21 protein by Western blot.RESULTS VAP inhibited the proliferation of H1299,the cells were blocked at G1 phase and cell apoptosis was increased compared to the control in a dose- and time-dependent manner. In addition VPA can upregulate the expression of p21 in H1299.CONCULSION By blocking cell cycle and inducing apoptosis in vitro,VPA inhibits the growth of H1299 cells,the machine may be related to the upregulation expression of p21.
关键词
丙戊酸钠 /
肺癌细胞H1299 /
细胞增殖 /
细胞周期 /
细胞凋亡 /
p21
{{custom_keyword}} /
Key words
sodium valproate /
H1299 lung cancer cell /
cell proliferation /
cell cycle /
cell apoptosis /
p21
{{custom_keyword}} /
中图分类号:
R965
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] DUENAS-GONZALEZ A, CANDELARIA M, PEREZ-PLASCENCIA C, et al. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors[J]. Cancer Treat Rev, 2008,34(3):206-222.[2] ATMACA A,AL-BATRAN S E,MAURER A,et al.Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial[J]. Br J Cancer,2007, 97(2): 177-182. [3] SHARMA S, SYMANOWSKI J, WONG B, et al.A phase ii clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy[J].Transl Oncol,2008, 1(3): 141-147. [4] JONES P A,MARTIENSSEN R. A blueprint for a human epigenome project: The AACR human epigenome workshop[J]. Cancer Res, 2005,65(24):11241-11246.[5] FREW A J, JOHNSTONE R W, BOLDEN J E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors[J]. Cancer Lett, 2009,280(2):125-133. [6] JOHNSTONE R W.Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer[J]. Nat Rev Drug Discov,2002,1(4):287-299.[7] FORTUNATI N, BERTINO S, COSTANTINO L, et al. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells[J]. Cancer Lett, 2008,259(2): 156-164.[8] LI X N, SHU Q, SU J M, et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC [J]. Mol Cancer Ther, 2005, 4(12): 1912-1922.[9] SINGH T, PRASAD R, KATIYAR S K. Inhibition of class I histone deacetylases in non-small cell lung cancer byhonokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo[J].Epigenetics, 2013,8(1):54-65.[10] WATANABE Y, HASHIMOTO Y, KAGAWA S,et al.Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells[J]. Cancer Gene Therapy,2012,19(11):767-722.[11] GLASER K B. HDAC inhibitors: Clinical update and mechanism-based potential[J].Biochem Pharmacol, 2007,74(5):659-671. [12] KENNICHI C D,LESLEY P,VICTORIA H,et al.Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor,diminisheslymphoproliferation in the Fas-deficient MRL/lpr_/_murine model of autoimmune lymphoproliferative syndrome (ALPS) [J].Exp Hematol,2009,37(4):487-494.[13] LUO H,LIU M Z,WANG H Y,et al.Proliferation inhibition of sodium valproate on lung cancer cell line A549[J].J Tongji Univ(Med Sci)(同济大学学报:医学版),2009,30(2):38-43.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
上海市科委引导项目资助(10411967500)
{{custom_fund}}